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Background: Many studies have revealed that homeobox-B7 (HOXB7) and miR-337 play important roles in different
types of human cancers. However, the relationship of HOXB7 and miR-337 in PDAC with clinicopathological factors
has not yet been examined and their biological roles remain to be explored.
Methods: Using quantitative real-time RT-PCR and immunohistochemical staining, the expression of HOXB7 mRNA,
miR-337, and HOXB7 protein in 44 PDAC samples was detected. Survival curves were made using follow-up data.
The relationship between clinical or pathological characteristics and the prognosis was analyzed.
Results: The expression levels of HOXB7 mRNA and HOXB7 protein were significantly elevated in PDAC samples
than that in non-malignant adjacent tissues. There were obvious differences in HOXB7 mRNA and proteins between
tumors of different diameters, differentiation, TNM stage, and lymph node status. The level of miR-337 was markedly
lower in tumor samples than in non-malignant adjacent tissues. The expression of miR-337 was related to TNM
stage and lymph node status. There were significant differences in survival curves between patients with tumors
<4 cm in diameter and patients with tumors ≥4 cm, among groups of well, moderately, and poorly differentiated
tumors, between groups with TNM stages I, II and III or IV, between groups with metastatic lymph nodes and
non-metastatic lymph nodes, among groups of HOXB7 protein expression negative (or weak) and positive, between
groups with low levels of miR-337 expression and with high levels of miR-337 expression. The levels of HOXB7
mRNA, HOXB7 protein, and miR-337 were found to be associated with longer survival.
Conclusion: The present study showed that HOXB7 was over-expressed and miR-337 was minimally expressed in
PDAC tissues, and their levels were related to TNM stage and lymph node status. The levels of HOXB7 mRNA,
HOXB7 protein, and miR-337 were associated with survival in PDAC patients. Results suggested that HOXB7 and
miR-337 could be used as determinants of PDAC patient prognosis.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1509730773118658.
Keywords: Pancreatic ductal adenocarcinoma (PDAC), HOXB7, miR-337Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the
most common causes of cancer-related death in the world,
and only <3% of patients survive for five years after diag-
nosis. PDAC is usually diagnosed at an advanced stage
and most patients are unsuitable for curative surgery [1,2].* Correspondence: ruizhang0001@126.com; zhaogq@zzu.edu.cn
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and functions of proteins, genes, and enzymes in PDAC.
The homeobox gene family has 39 members. They are
classified into four groups (HOX-A, HOX-B, HOX-C,
and HOX-D) located on chromosomes 7p, 17q, 12q, and
2q, respectively. The HOX genes encode transcriptional
factors that regulate gene expression and control mor-
phogenesis and cell differentiation. Aberrant expression
of HOX genes has been reported in many human cancers
[3-8] including hepatocellular carcinoma [9], ovarian car-
cinoma [10], breast cancer [11], and leukemia [12]. Studies
have shown that HOXB7 plays an important role inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinicopathologic characteristics of the 44




Age (years) <60 26
≥60 18
Diameter (cm) <4 33
≥4 11
Position Head 31




TNM stage I or II 20
III or IV 24
Node status Negative 24
Positive 20
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[13-18]. MicroRNAs (miRNAs) are short, non-coding
RNAs that regulate gene expression post-transcriptionally
by binding to the 3′UTR of target mRNAs [19,20]. MiR-
NAs were found to play fundamentally important roles in
the pathogenesis, progression and metastasis of PDAC
[21-24]. Many studies have shown miR-337 to be involved
in tumor cell proliferation, migration, and invasion [25]. Its
expression was found to be related to the tumor prognosis
in some patients [26-28]. miR-337 has been identified as a
key regulator of HOX and TGFBR2 [29,30]. However, the
relationship between the expression of HOXB7 mRNA and
miR-337 and clinicopathological factors is still unclear. The
biological roles played by HOXB7 and miR-337 in PDAC
remian to be examined.
In this study, the roles of HOXB7 and miR-337 in
PDAC were examined by analyzing 44 cases of PDAC
patients retrospectively between 2002 and 2006, detect-
ing the expression of HOXB7 mRNA and miR-337, and
assessing the relationship between HOXB7 mRNA and
miR-337 and survival time.
Materials and methods
Clinical sample collection
PDAC samples were obtained from 44 patients diag-
nosed with PDAC between January 2002 and December
2006 at the First Affiliated Hospital of Zhengzhou
University and Wuhan General Hospital of Guangzhou
Military. Patients who had PDAC but had received che-
moradiotherapy before surgical operation were excluded.
Medical records of the 44 patients provided information
regarding gender, age, tumor diameter, position, histology,
pathological stage, TNM stage, degree of lymph node me-
tastasis and survival time. Of the 44 patients, 28 were male
and 16 were female. There were 20 cases with lymph node
metastasis and 20 cases without lymph node metastasis.
Forty-four paired PDAC and non-malignant adjacent
tissues (located more than 5 cm from the tumors) were
obtained from PDAC patients who underwent primary
surgical resection with informed consent. The diagnosis
was established through clinical, biochemical, and radio-
logical findings and supported by pathological examina-
tions. These samples were snap-frozen in liquid nitrogen
after resection. This study was approved by the Research
Ethics Committee of Zhengzhou University, China, and
the samples were obtained with all patients’ informed
consent (Table 1).
Immunohistochemistry
Polyclonal rabbit anti-HOXB7 (Santa Cruz) was used
to detect the HOXB7 protein. Immunostaining was
performed using the streptavidin-biotin peroxidase
complex method. After visualized with DAB coloration kit
(Fuzhou Maixin) and counterstained with hematoxylin.The sections were dehydration, transparency, and
mounting. Reactions without primary antibodies served as
control reactions.
Quantitative real-time PCR (qRT-PCR)
Relative levels of miR-337 mRNA in PDAC tissues were
determined by quantitative real-time RT-PCR. Total RNA
was extracted using an RNA Extraction Kit (Qiagen) and
cDNA was extracted using a miScript Reverse Transcrip-
tion Kit (Qiagen), all according to the manufacturer’s
instructions. Relative expression of miR-337 was calcu-
lated using the comparative cycle threshold (CT) (2-△△Ct)
method with U6 snRNA as the endogenous control to
normalize the data. For the detection of HOXB7 mRNA,
reverse transcription and PCR were performed using ABI
TaqMan PCR Master Mix (Applied Biosystems). β-actin
was amplified in parallel and served as an internal control.
The primers used were as follows: HOXB7, 5′ AGCAG
AGGGAC TCGGACTTG 3′ (foward), 5′ CTCGTTTGC
GGTCAGTTCCT 3′ (reverse), Probe 5′ FAM-TAACTTC
CGGATCTACCCCTGGATGCG-TAMMR 3′; β-actin, 5′
TTCACTTCTTCAGTTCTGCCATCT 3′ (foward), 5′
CCAAGCTTTTCTCAGTCC CATAA 3′ (reverse), Probe
5′ FAM- TCAAAGGGCTCCAGCCTCACTCAGTC -TA
MMR 3′. The corresponding CT values were recorded
with ABI Prism7500 SDS Software, and then the relative
expression level of HOXB7 was calculated according to
the formula: 2-△△Ct.
Statistical analysis
Statistical analysis was performed using SPSS17.0 soft-
ware. Data were expressed as means ± standard deviation
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tween two samples. The relationships between HOXB7
(or miR-337) expression and clincopathologic characteris-
tics were tested using Chi square test. Survival curves
were plotted by Kaplan-Meier method and compared
using the log-rank test. P values less than 0.05 were con-
sidered statistically significant.
Results
HOXB7 mRNA was over-expressed in PDAC samples
The relative expression level of HOXB7 mRNA was
significantly higher in 44 PDAC tissue samples (P<0.01,
1.313 ± 0.218) than that in non-malignant adjacent tissues
(0.368 ± 0.138) (Figure 1). Statistical differences were
found between different diameter (P = 0.033), differenti-
ation (P = 0.028), TNM stage (P = 0.010), and lymph
node status (P = 0.014). There were no statistically sig-
nificant differences between patients of different genders
(P = 0.795), ages (P = 0.631), or tumor sites (P = 0.690)
(Table 2).
HOXB7 protein levels were high in PDAC samples
HOXB7 showed positive immune-reactivity, primarily in
the cytoplasm of the cells (Figure 2). The relative amount
of positive HOXB7 protein was significantly higher in
PDAC tissue samples (P<0.01, 65.9%) than in non-malig-
nant adjacent tissues (0%). Elevated expression of HOXB7
protein in the tumor was correlated with different tumors
of different diameters (P = 0.043), levels of differentiation
(P = 0.009), TNM stage (P = 0.008), and lymph node status
(P = 0.015). The expression of HOXB7 protein was not
associated with genders (P = 0.764), age (P = 0.930), or
tumor site (P = 0.398) (Table 2).
miR-337 levels were low in PDAC samples
The relative expression level of miR-337 was markedly lower
in PDAC tissue samples (P<0.01) than in correspondingFigure 1 HOXB7 mRNA and miR-337 expression in 44 human PDAC t
Relative level of HOXB7 mRNA in tumor tissues increased compare to non-
tumor tissues was lower than in non-malignant adjacent tissues (P<0.01). Tnon-malignant adjacent tissues (Figure 1). Low expression
of miR-337 was found to be related to TNM stage
(P = 0.002) and lymph node status (P = 0.001). The
expression of miR-337 was not found to be related
to gender (P = 0.860), age (P = 0.132), tumor diameter
(P = 0.228), tumor site (P = 0.521) or differentiation
(P = 0.210) (Table 2).
Expression of HOXB7 mRNA was negatively correlated to
expression of miR-337
Pearson’s product moment correlations were used to
analyze the relationship between the level of HOXB7
mRNA and the level of miR-337 in 44 PDAC tissue sam-
ples. The level of HOXB7 mRNA in cancer had a negative
correlation with the level of miR-337 (r = −0.719, P<0.01).
Expression levels of HOXB7 and miR-337 were associated
with longer survival in patients with PDAC
Survival curves were drawn using SPSS 17.0 software using
the Kaplan-Meier method. Significant differences in sur-
vival curves were observed between patients with <4 cm
tumors and patients with ≥4 cm tumors (χ2 = 5.306,
P = 0.021), among groups with good, moderate, and
poor differentiation (χ2 = 8.322, P = 0.016), between
groups with TNM stages of I, II and either III, IV (χ2 =
8.958, P = 0.003), between the lymph node metastatic
group and non-metastatic group (χ2 = 21.340, P = 0.000),
among groups in which HOXB7 protein expression was
negative (or weak) and positive (χ2 = 6.256, P = 0.012),
between groups with low levels of miR-337 and expression
and those in which miR-337 was over-expressed (χ2 =
9.181, P = 0.002). However no significant differences were
observed between male and female patients (χ2 = 0.615,
P = 0.433), between patients <60 years old and ≥60 years
old (χ2 = 2.857, P = 0.091), or between pancreatic head car-
cinoma and pancreatic body or tail carcinoma (χ2 = 0.169,
P = 0.681) (Figure 3).issues. HOXB7 mRNA and miR-337 were detected using qRT-PCR. A)
malignant adjacent tissues (P<0.01). B) The relative level of miR-337 in
human PDAC tissues, N non-malignant adjacent tissues.
Table 2 Expression of HOXB7 mRNA, protein, and miR-337 in the pancreatic ductal adenocarcinoma cases
Parameter HOXB7 protein HOXB7 mRNA miR-337
Negative (n) Positive (n) P value Expression level P value Expression level P value
Gender
Male 10 18 0.764 1.319 ± 0.221 0.795 0.2900 ± 0.09854 0.860
Female 5 11 1.302 ± 0.218 0.2981 ± 0.08573
Age (years)
<60 9 17 0.930 1.296 ± 0.229 0.631 0.306 ± 0.105 0.132
≥60 6 12 1.338 ± 0.203 0.274 ± 0.072
Diameter(cm)
<4 14 19 0.043* 1.259 ± 0.219 0.033* 0.305 ± 0.097 0.228
≥4 1 10 1.474 ± 0.107 0.257 ± 0.072
Location
Head 12 19 0.398 1.308 ± 0.222 0.690 0.304 ± 0.095 0.521
Body or tail 3 9 1.325 ± 0.215 0.263 ± 0.084
Differentiation
Well 6 3 0.009** 1.221 ± 0.142 0.028* 0.312 ± 0.082 0.210
Moderate 9 16 1.279 ± 0.243 0.305 ± 0.102
Poor 0 10 1.481 ± 0.084 0.245 ± 0.066
TNM stage
I or II 11 9 0.008** 1.161 ± 0.214 0.010* 0.338 ± 0.109 0.002**
III or IV 4 20 1.440 ± 0.117 0.256 ± 0.057
Nodal status
Negative 12 12 0.015* 1.199 ± 0.220 0.014* 0.330 ± 0.105 0.001**
Positive 3 17 1.450 ± 0.111 0.248 ± 0.048
*P <0.05, **P <0.01.
Figure 2 Immunohistochemical staining of HOXB7 in PDAC tissue sections. A) and B) HOXB7 was strongly positive. C) HOXB7 was positive.
D) HOXB7 was weakly positive.
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Figure 3 Kaplan-Meier curves of the clinical outcome in PDAC patients. A) Survival curves of different tumor size in patients with PDAC
(P=0.021). B) Survival curves of differentiations in patients with PDAC (P=0.016). C) Survival curves of different TNM stages in patients with PDAC
(P=0.003). D) Survival curves of lymph node metastatic group and non-metastatic group in patients with PDAC (P=0.000). E) Survival curves of
different HOXB7 protein level groups in patients with PDAC (P=0.012). F) Survival curves of different miR-337 level groups in patients with
PDAC (P=0.002).
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Pancreatic cancer has extremely poor prognosis. Many
protein, DNA, and RNA-based markers have been shown
to be related to the diagnosis and prognosis of pancreatic
cancer. MIB-1 (directed against the Ki-67 antigen) helps
to determine neuroendocrine pancreatic cancer grade and
prognosis [31]. The expression of MUC1 is related to poor
prognosis in pancreatobiliary pancreatic head tumors. The
expression of MUC5AC is associated with good prognosis
and little vascular invasion of PDAC [32].
Previous studies have shown overexpression of HOXB7
to be closely associated with the clinical progression andpoor prognosis of patients with breast cancer, oral squa-
mous cell carcinomas, ovarian cancer, lung adenocar-
cinoma, and esophageal squamous cell cancer [33-36].
The expression of HOXB7 is visibly related to the invasive
and aggressive characteristics of human colorectal cancer
(high Dukes stage, T stage, distant metastasis-positive tu-
mors, and high proliferation index) and to poor survival of
patients [37]. High levels of HOXB7 expression have been
detected in both PDAC cell lines and patient samples.
HOXB7 knockdown and overexpression in PDAC cell
lines caused decreased and increased invasion, respectively
[38]. HOXB7 was found to be involved in pancreatic
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[39]. High HOXB7 protein expression in the tumor tissues
was recently found to be correlated with lymph node me-
tastasis and to be independent predictor of shorter overall
survival [38]. This study was performed using immunohis-
tochemical techniques on a large cohort of PDAC.
Using a tri-modal approach, HOXB7 was identified as
the target for miR-337. In turn, vascular endothelial
growth factor (VEGF) was found to be a downstream
transcript regulated by HOXB7 [40]. miR-337 down-
regulation was found to promote cellular proliferation,
clonogenicity, migration, and invasion and increase tumor
cell proliferation and angiogenesis in vivo. It was also
found to be closely associated with shorter disease-free
survival for cervical cancer. Considering the many reports
showing the clinical relevance of expression of HOXB7
and miR-337, it is likely that both HOXB7 and miR-337
are co-regulatory molecules and that they are involved in
the carcinogenesis and progression of tumors. The present
study confirmed HOXB7 overexpression and miR-337
downregulation in PDAC samples. Significantly higher
levels of HOXB7 mRNA and protein were detected in
PDAC samples than in non-malignant adjacent tissues.
Levels of HOXB7 mRNA and protein expression were
positively correlated with diameter, differentiation, TNM
stage, and lymph node status, but it was not correlated
with gender, age, or position. miR-337 showed markedly
less expression in PDAC tissue samples than in non-
malignant adjacent tissues. Declines in the expression of
miR-337 were found to be related to TNM stage and
lymph node status but not to gender, age, diameter,
position, or differentiation. The level of HOXB7 mRNA
showed a negative correlation with the level of miR-337 in
PDAC samples. There were significant differences in sur-
vival curves between patients with tumors <4 cm in diam-
eter and patients with tumors ≥4 cm in diameter, among
groups of tumors that are well, moderately, and poorly
differentiated, between groups with TNM stages I, II and
III or IV, between lymph node metastatic group and non-
metastatic group, among groups of negative (or weak) and
positive for HOXB7 protein expression, between groups
with low levels of miR-337 expression and miR-337 over-
expression but no significant differences between patients
of different sexes, ages, and tumor sites. In conclu-
sion, the present findings not only suggest that the
existence of HOXB7 overexpression and miR-337
downregulation in PDAC samples but also that the
expression of HOXB7 and miR-337 is correlated with
features related to poor prognosis in PDAC patients.
Altered expression levels of HOXB7 and miR-337
may be important to invasion and metastasis of PDAC,
and HOXB7 and miR-337 may be suitable for use as
markers in the assessment and identification of high-risk
PDAC patients.Abbreviations
PDAC: Pancreatic ductal adenocarcinoma; HOXB7: Homeobox B7.
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